Engineering CAR-T Cells for Next-Generation Cancer Therapy

被引：480

作者：

Hong, Mihe ^{[1
]}

Clubb, Justin D. ^{[1
]}

Chen, Yvonne Y. ^{[1
,2
,3
]}

机构：

[1] Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, Parker Inst Canc Immunotherapy Ctr, Los Angeles, CA 90095 USA

来源：

CANCER CELL | 2020年 / 38卷 / 04期

关键词：

CHIMERIC-ANTIGEN-RECEPTOR; FIBROBLAST ACTIVATION PROTEIN; NATURAL-KILLER-CELLS; ANTITUMOR EFFICACY; SUICIDE-GENE; TUMOR MICROENVIRONMENT; 4-1BB COSTIMULATION; CHECKPOINT BLOCKADE; SAFETY SWITCH; TGF-BETA;

D O I：

10.1016/j.ccell.2020.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have shown remarkable success in treating patients with hematologic malignancies and revitalized the field of adoptive cell therapy. However, realizing broader therapeutic applications of CAR-T cells necessitates engineering approaches on multiple levels to enhance efficacy and safety. Particularly, solid tumors present unique challenges due to the biological complexity of the solid-tumor microenvironment (TME). In this review, we highlight recent strategies to improve CAR-T cell therapy by engineering (1) the CAR protein, (2) T cells, and (3) the interaction between T cells and other components in the TME.

引用

页码：473 / 488

页数：16

共 183 条

[1] IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype [J].

Alizadeh, Darya ;

Wong, Robyn A. ;

Yang, Xin ;

Wang, Dongrui ;

Pecoraro, Joseph R. ;

Kuo, Cheng-Fu ;

Aguilar, Brenda ;

Qi, Yue ;

Ann, David K. ;

Starr, Renate ;

Urak, Ryan ;

Wang, Xiuli ;

Forman, Stephen J. ;

Brown, Christine E. .

CANCER IMMUNOLOGY RESEARCH, 2019, 7 (05) :759-772

[2] Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System [J].

Avanzi, Mauro P. ;

Yeku, Oladapo ;

Li, Xinghuo ;

Wijewarnasuriya, Dinali P. ;

van Leeuwen, Dayenne G. ;

Cheung, Kenneth ;

Park, Hyebin ;

Purdon, Terence J. ;

Daniyan, Anthony F. ;

Spitzer, Matthew H. ;

Brentjens, Renier J. .

CELL REPORTS, 2018, 23 (07) :2130-2141

[3] Human CD8 T cells generated in vitro from hematopoietic stem cells are functionally mature [J].

Awong, Geneve ;

Herer, Elaine ;

La Motte-Mohs, Ross N. ;

Zuniga-Pfluecker, Juan Carlos .

BMC IMMUNOLOGY, 2011, 12

[4] The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells [J].

Bachmann, Michael .

IMMUNOLOGY LETTERS, 2019, 211 :13-22

[5] Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma [J].

Batra, Sai Arun ;

Rathi, Purva ;

Guo, Linjie ;

Courtney, Amy N. ;

Fleurence, Julien ;

Balzeau, Julien ;

Shaik, Rahamthulla S. ;

Nguyen, Thao P. ;

Wu, Meng-Fen ;

Bulsara, Shaun ;

Mamonkin, Maksim ;

Metelitsa, Leonid S. ;

Heczey, Andras .

CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) :309-320

[6] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].

Beatty, Gregory L. ;

Haas, Andrew R. ;

Maus, Marcela V. ;

Torigian, Drew A. ;

Soulen, Michael C. ;

Plesa, Gabriela ;

Chew, Anne ;

Zhao, Yangbing ;

Levine, Bruce L. ;

Albelda, Steven M. ;

Kalos, Michael ;

June, Carl H. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120

[7] Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells [J].

Boice, Michael ;

Salloum, Darin ;

Mourcin, Frederic ;

Sanghvi, Viraj ;

Amin, Rada ;

Oricchio, Elisa ;

Jiang, Man ;

Mottok, Anja ;

Denis-Lagache, Nicolas ;

Ciriello, Giovanni ;

Tam, Wayne ;

Teruya-Feldstein, Julie ;

de Stanchina, Elisa ;

Chan, Wing C. ;

Malek, Sami N. ;

Ennishi, Daisuke ;

Brentjens, Renier J. ;

Gascoyne, Randy D. ;

Cogne, Michel ;

Tarte, Karin ;

Wendel, Hans-Guido .

CELL, 2016, 167 (02) :405-+

[8] FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma [J].

Bouchkouj, Najat ;

Kasamon, Yvette L. ;

de Claro, R. Angelo ;

George, Bindu ;

Lin, Xue ;

Lee, Shiowjen ;

Blumenthal, Gideon M. ;

Bryan, Wilson ;

McKee, Amy E. ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2019, 25 (06) :1702-1708

[9] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[10] Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts [J].

Cartellieri, M. ;

Feldmann, A. ;

Koristka, S. ;

Arndt, C. ;

Loff, S. ;

Ehninger, A. ;

von Bonin, M. ;

Bejestani, E. P. ;

Ehninger, G. ;

Bachmann, M. P. .

BLOOD CANCER JOURNAL, 2016, 6 :e458-e458

← 1 2 3 4 5 6 7 8 9 10 →